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INTRODUCTION 
Tissue transplants between genetically dissimilar 
individuals or, more specifically, from one inbred strain 
to another unrelated inbred strain are known as "homo- 
grafts" . Transplants between genetically uniform animals 
of the same inbred strain are "isografts". Characteris¬ 
tically, homografts of mature tissue will not grow and 
isografts wall. For exploration of these and related phe¬ 
nomena transplantable tumor grafts, because of the ease 
with w^hich this tissue can be transplanted, are often the 
research tool of choice although normal tissue grafts may 
be preferred in some instances. Highly inbred strains of 
mice are convenient experimental animals because of the 
certainty with which genetic factors may be controlled 
and the relatively low cost per animal. The response of 
a host to a graft of tumor, or normal tissue, from a gene¬ 
tically dissimilar donor leading to ultimate graft rejec¬ 
tion and destruction is known as the "homograft reaction". 
A host receiving two successive grafts from the same, or 
genetica.lly similar, foreign hosts rejects the second 
graft more rapidly than the first. This accelerated re¬ 
action to a second graft is termed the "second set response". 
Many investigators have found that the "second set 
response" under- certain conditions will not take place. 
As early as 19C7 Flexner and Jobling reported that a second 
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gr?ft of a transplantable rat sarcoma grew progressively 
in a. large proportion of' rats in which an initial graft 
of the same tumor had previously regressed (l). The first 
systematic studies on abrogation of the "second set response" 
were done by Casey and his co-workers with the Brown-Pearce 
tumor in rabbits and transplantable tumors in mice (2-8). 
In animals which were pretreated with killed homologous tu¬ 
mor tissues, grafts of tumor were found to grow- and metas¬ 
tasize more widely and rapidly. Further, this effect was 
proved specific, in that it was only produced by killed 
tissue of the tumor to be transplanted. 
Kaliss demonstrated the essential unifying phenomenon 
in these and similar studies pertaining to the induced sur¬ 
vival of tumor homograf'ts. He found that sera produced 
in mice or rabbits by inoculating killed tissues, or using 
live transplants, when injected into prospective hosts 
prior to grafting the tumor would insure survival of the 
grafts (9-11). By zone electrophoresis and salt fraction¬ 
ation this effect vres demonstrated to be due to an antibody 
in the sera. The active fraction was in the globulin por¬ 
tion, probably the gemma globulin (12). So the paradox 
of enhanced growth of tumor grafts following prior treat¬ 
ment intended to heighten resistance was the result of' ex¬ 
posure of the graft to antiserum produced against it. 
This progressive growth of a homograft of a trans¬ 
plantable mouse tumor in a foreign host strain of mice as 
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a result of the exposure of the graft to antiserum is 
termed "immunological enhancement" (13,14-) . The anti¬ 
serum may he produced by active immunization with lyo- 
philized tumor or liver, kidney or spleen, from the strain 
of mouse to which the tumor is native (15-19). Passive 
immunization can be produced by injection of anti-tissue 
sera (1C-12). 
Several hypotheses have been advanced as an explana¬ 
tion of the action of antiserum in relation to enhanced 
growth of the graft. A few are considered by Kaliss and 
Bryant in their recent paper (20). A theory not discussed 
by them has been suggested by Snell (21,29) and by Billing- 
ham, Brent and Medawar (23). They propose that a "walling 
off" of the tumor graft by the antiserum may occur w'hich 
will prevent the tumor cells from antigenically stimulat¬ 
ing the host's lymphoid tissue and thus avoid the "cellu¬ 
lar response" thought to be responsible for the destruc¬ 
tion of the graft (24-26). As Snell says, "The sugges¬ 
tion is that antiserum prevents or delays the antigens 
of the homograft, or at least effective antigens, from 
reaching the regional lymph nodes. The nodes are thus 
unable to generate the cellular immune factor which is 
the principal agent of graft destruction. Snell has called 
this a 'walling off' of the graft, and Billingham et al. 
an 'afferent inhibition' " (22). 
It was the purpose of this experiment to test the 
above hypothesis and, if possible, to shea further light 
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on the mechanism of' "immunological enhancement". If tumor 
cells could be found in the lymph nodes of immunologically 
enhanced animals, and particularly if they could be found 
there within a short time after tumor grafting, then this 
would be direct proof that the "walling off" or "afferent 
inhibition" theory is fallacious. If viable tumor cells 
reach the lymph nodes, no more effective antigenic stimu¬ 
lus could be necessary or even possible. The design of 
this experiment is similar, with certain technical modi¬ 
fications, to work of Mitchison although he found no viable 
tumor cells in lymph nodes draining the area of regression 
of a tumor (25,26). 
MATERIALS AND METHODS 
The transplantable mouse tumor used was Sarcoma I, 
which is indigenous to the inbred A strain of mice and 
grows in solid form when injected subcutaneously and In 
ascites form when injected intraperitoneally. The strains 
of mice used were: A/Ks, A/Jax and C57BL/Ks (a C57BL/6 
subline). A/Ks and A/Jax are genetically similar, and 
grafts of Sarcoma I will grow and kill almost IOC per cent 
of those inoculated within five weeks. The C57BL/Ks strain 
is normally resistant to grafts of Sarcoma I. In C57BL/Ks 
hosts Sarcoma I grafts characteristically grow for about 
12 days then rapidly regress. All the mice used in this 
experiment were 4 to 7 months old except for the A/Jax mice 
used for confirmation of tumors which were 2 to 3 months old. 
. 
. 
• '■ 
. 
, 
. 
There were 4 large groups of mice. Group I was com¬ 
posed of C57BL/Ks mice equally divided as to sex. This 
group received 4 intraperitoneal injections of lyophilized 
Sarcoma I over a period of 13 days. Each injection was 
composed of 4 mgm dry weight of the freeze dried tumor in 
0.5 ml physiological saline. Ten days after the last in¬ 
jection of lyophilized Sarcoma I each mouse received in 
the flank a subcutaneous inoculation of 600,000 cells of 
Sarcoma I. This inoculum was prepared by taking Sarcoma I 
ascites fluid and counting the cells by the ordinary white 
cell count procedure and diluting the ascites fluid with 
physiological saline to the desired concentration oi cells. 
Group II was composed of C57BL/Ks mice equally divided 
as to sex. This group received an intraperitoneal injec¬ 
tion of C.5 ml of pooled anti-Sercoma I sera. These sera 
were obtained by bleeding C57BL/Ks mice after primary im¬ 
munization with a solid inoculum of' Sarcoma I or bleeding 
after subsequent booster shots of 1 to 10 homogenates of 
frozen Sarcoma I. They were prepared by allowing them to 
remain for 2 hours at room temperature then spinning down 
the clot and pipetting off the serum which was frozen at 
-23°C. until used. On the same day as the injection of the 
anti-Sarcoma I serum these mice were inoculated subcuta¬ 
neously with 600,000 cells of Sarcoma I prepared as pre¬ 
viously described. 
Group III v/a.s composed of C57BL/Ks mice and Group IV 
of A/Ks mice. These were equally divided as to sex. 
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They received no pretreatment, but were inoculated sub¬ 
cutaneously with 6CC,CCC Sarcoma I cells prepared as de¬ 
scribed above. 
Each of these large groups was subdivided into 5 
smaller groups composed of 6 males ana 6 females each. 
Cne of these subgroups from each large group was sacri¬ 
ficed 3,5,7, end 14 days after inoculation with Sarcoma I 
tumor cells. "When the animals were sacrificed, the axil¬ 
lary, brachial and inguinal lymph nodes from the side of 
implantation of the tumor cells were removed, trimmed free 
of fat and minced by chopping the nodes finely with scissors 
in a single drop of physiological saline on a sterile glass 
slide. This mince was injected through a. sterile trocar 
intraperitoneally after a small transverse incision in the 
abdominal skin had been made with sterile scissors. All 
the lymph node inoculations were made into A/Es mice, a 
substrain of the A/Jax strain to which Sarcoma I is indi¬ 
genous. The wound was closed with collodion to minimize 
infection or possible leakage of the injected material. 
Occasionally lymph nodes were found overgrown by tumor, 
and these were discarded and not transferred. Two node 
donor mice per host were used, and nodes were transferred 
only from males to a male and. from females to a female. 
The contralateral lymph nodes were treated in the same 
way as the ipsilateral nodes just described. 
The fifth subgroups from each of the larger groups 
were not sacrificed and the grovrth of the grafts was 
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followed by periodic palpation until the mice either died 
with a progreesively growing tumor or remained without an 
evident sign of growth for a consecutive period of two 
months at which time they were sacrificed and autopsied. 
If no evidence of tumor was found, they were classified 
as negative. 
The A/Ks mice which received the lymph nodes w^ere ob¬ 
served daily for the appearance of ascites or solid tumors. 
When a mouse developed ascites, it was sacrificed and 1 cc 
of the ascitic fluid was injected subcutaneously into 
A/Jax mice. Slide preparations were also made of the 
ascitic cells, and an autopsy was performed on each mouse. 
The A/Jax mice had to develop solid tumors which grew; to 
their death before the A/Ks mouse was considered to have 
had tumor cells in the lymph nodes it received. All slides 
were reviewed and confirmed as showing sheets of tumor cells. 
The A/Ks mice w,hich did not develop tumors w;ere observed 
for 3 months and then sacrificed and autopsied to search 
for any evidence of tumors. 
RESULTS 
The results of this experiment are given in Table I. 
Twenty four animals developed tumorous ascites. Each 
recipient group was composed of 6 males and 6 females 
except In 3 groups, as noted in Table I, in which animals 
died of unrelated causes. Of the 24 animals which demon- 
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strated that the nodes they received contained viable tumor 
cells, 6 were hosts for node donors in Group I, the "ac¬ 
tively enhanced" group; 3 were hosts for node donors in 
Group II, the "passively enhanced" group; 8 were from Group 
III, the hosts whose donor's nodes were supposedly resis¬ 
tant; and 7 were from Group IV, the hosts whose donor's 
nodes were considered maximally susceptible to invasion 
by tumor cells. Viable tumor cells were present in the 
contralateral nodes received by 5 animals. As to sex, 
12 males and 12 females died with tumorous ascites. In 
general it developed earlier in females, the first female 
dying 22 days after receiving nodes, and 7 days later 
8 females, as opposed to 3 males, had been killed by 
the tumor. 
. 
TABLE I 
Key: 
Column 1: 
Column 2: 
Column 3: 
Column 4: 
Column 5: 
Column 6: 
Column 7: 
Subgroups 
Pretreatment of' node doners 
Lymph node doner strain 
Days from donor tumor inoculation to sacri¬ 
fice end node +ransfer 
Number of recipient mice dying with tumor / 
number inoculated with nodes 
Number of males dying / number of females dying 
Mice dying that received contralateral nodes 
1 2 3 4 5 6 7 
Group I: 
A Fr. dr. Sal 
T5 H 
C5JBL/KS 3 
5 
l/l2 
5/12 
1K/CF 
3M/2F 
C 
0 
ii 7 0/12 0 0 it 14 0/11 0 C 
n 
not sacrificed (control group; 
Group II: 
F Anti-Sal 
n " 
serum 3 1/12 
5 0/12 
7 2/12 
14 0/12 
not sacrificed 
1M/0F 0 
0 0 
2M/CF C 
0 0 
(control group) 
Group III: 
K Nothing 
L ,V 
C57BL/KS ** y 3/12 2M/1F 0 
ti 5 4/12 3M/1F IF 
M " ii 7 1/11 1M/0F 0 
N " ii 14 0/12 C 0 
0 " ii not ! sacrificed (control group) 
Group IV: 
P 
Q 
R 
S 
T 
Nothing 
II 
II 
It 
A/Ks 
ii 
it 
it 
ii 
3 2/12 
5 4/12 
7 0/12 
14 1/12 
not sacrificed 
2M/CF 0 
1M/3F 1M/3F 
0 0 
1M/0F 0 
(control group) 
- 
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DISCUSSION 
The limits of this tumor-donor-host combination should 
be defined by the groups composed of A/Ks donors (Group IV, 
Table I) since this is the strain to which Sarcoma I is 
native. These maximally susceptible donor animals should 
have produced the greatest possible number of lymph nodes 
containing viable tumor cells. As an approximate indica¬ 
tion of the sensitivity of the method used in this exper¬ 
iment, Kaliss found that 2CC to 50C Sarcoma I cells in¬ 
jected intraperitoneally into A/Ks mice will kill 6C per 
cent of those injected in 22 to 25 days (Kaliss, unpub¬ 
lished data). 
The presence of viable tumor cells in lymph nodes 
excised from mice in Groups I and II is evidence that tu¬ 
mor grafts in "immunologically enhanced” mice are not "walled 
off". The finding of metastases as ea.rly as 3 days (Sub¬ 
groups A and F) after tumor inoculation indicates that 
"afferent inhibition" plays no important role in enhance¬ 
ment. These results make improbable the hypothesis that 
antiserum prevents or delays effective antigens of the 
homogrsft from reaching the regional lymph nodes. 
Viable tumor cells being present in the nodes of 8 
Group III mice is at variance with the findings of Mitch- 
ison wrho "repeatedly implanted in mice susceptible to the 
tumor lymph nodes draining" the area, of regression of a. 
tumor in order to test for the presence of viable tumor 
. 
. , J 
cells’' and found "the transferred nodes never gave rise 
to tumors" (26). Perhaps an explanation of this discre¬ 
pancy lies in the different methods used to inject lymph 
nodes. Use of a trocar made possible the injection of the 
entire inoculum of minced nodes, while enough of the mince 
might have remained in the 19 gauge needle and the bored 
out nozzle of the C.25 ml syringe used by Mitchison so 
that a critical concentration of tumor cells was not in¬ 
jected. Mitchison does not indicate how many nodes com¬ 
posed. an inoculum for a single mouse. 
The fact that all of the nodes containing viable tu¬ 
mor cells which were from the contralateral side of the 
donor were excised on the fifth day after tumor inocula¬ 
tion suggests that there may be a critical time during 
which hematogenous metastases occur. That lymphatic me¬ 
te stases continue to occur is demonstrated, by the animals 
which received nodes on the seventh and twelfth post ino¬ 
culation days (Subgroups H, M, and S). These factors pro¬ 
bably vary with the host-tumor combina.tion under study. 
' 
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SUMMARY 
Sarcoma I was inoculated into 4 groups of mice: 
(1) actively enhanced mice, (2) passively enhanced mice, 
(3) unenhanced mice oi a, strain normally resistant to 
grafts of this tumor and (4) mice of the, strain in which 
this tumor is propoga.ted.. The lymph nodes from these mice 
were excised at 3,5,7, and 14 day intervals after implan¬ 
tation and inoculated into mice to which the tumor is in¬ 
digenous. Twenty four animals developed tumors, demon¬ 
strating the lymph nodes they received contained viable 
tumor cells. Nine of these mice received nodes from ac¬ 
tively or passively enhanced doners proving that sufficient 
antigenic stimulus is not lacking or delayed in immunologi- 
cally enhanced animals. This makes it seem unlikely that 
"walling: off" or "afferent inhibition" can be a valid ex¬ 
planation of the mechanism of action of antisera in this 
phenomenon. Finding viable tumor cells in lymph nodes 
draining the area of regression of a tumor in eight animals 
of Group III conflicts with Mitchison's reported results. 
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A C57BL/Ks mouse with a subcutaneous tumor 
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